• Immuneering plans a potentially registrational Phase 2 trial of atebimetinib with chemotherapy for anaplastic thyroid cancer, subject to regulatory discussions.
• The study would enroll approximately 60 patients whose cancer progressed on standard treatment, including all-comers and BRAF V600E cohorts.
• An investigational new drug application is planned by year-end 2026, with first patient dosing targeted for mid-2027, subject to regulatory clearance.
• Topline results could be available 12–18 months after dosing begins.
• Preclinical findings supporting the combination’s rationale will be presented November 18, 2026, at the EORTC-NCI-AACR Symposium in Barcelona.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120730PRIMZONEFULLFEED9876020) on November 12, 2026, and is solely responsible for the information contained therein.